120 related articles for article (PubMed ID: 33229107)
1. Evaluation of manufacturing feasibility and safety of an MDCK cell-based live attenuated influenza vaccine (LAIV) platform.
Ganguly M; Yeolekar L; Tyagi P; Sagar U; Narale S; Anaspure Y; Tupe S; Wadkar K; Ingle N; Dhere R; Scorza FB; Mahmood K
Vaccine; 2020 Dec; 38(52):8379-8386. PubMed ID: 33229107
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and efficacy comparison of MDCK cell-based and egg-based live attenuated influenza vaccines of H5 and H7 subtypes in ferrets.
Yeolekar LR; Guilfoyle K; Ganguly M; Tyagi P; Stittelaar KJ; van Amerongen G; Dhere RM; BerlandaScorza F; Mahmood K
Vaccine; 2020 Sep; 38(40):6280-6290. PubMed ID: 32741671
[TBL] [Abstract][Full Text] [Related]
3. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells.
Hussain AI; Cordeiro M; Sevilla E; Liu J
Vaccine; 2010 May; 28(22):3848-55. PubMed ID: 20307595
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers.
Heldens J; Hulskotte E; Voeten T; Breedveld B; Verweij P; van Duijnhoven W; Rudenko L; van Damme P; van den Bosch H
Vaccine; 2014 Sep; 32(39):5118-24. PubMed ID: 24858566
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of tumorigenic potential of high yielding cloned MDCK cells for live-attenuated influenza vaccine using in vitro growth characteristics, metastatic gene expression and in vivo nude mice model.
Vepachedu RS; Menon A; Hussain AI; Liu J
Biologicals; 2012 Nov; 40(6):482-94. PubMed ID: 22902973
[TBL] [Abstract][Full Text] [Related]
6. Rapid clearance of intranasally administered DNA from rat tissues.
Tabor DE; Mani S; Shen X; Chen X; Engbers C; Jacobson S; Broome R; Liu J; Justewicz D; Galinski MS
Biologicals; 2013 Jul; 41(4):247-53. PubMed ID: 23665302
[TBL] [Abstract][Full Text] [Related]
7. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process.
George M; Farooq M; Dang T; Cortes B; Liu J; Maranga L
Biotechnol Bioeng; 2010 Aug; 106(6):906-17. PubMed ID: 20589670
[TBL] [Abstract][Full Text] [Related]
8. Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines.
Shin D; Park KJ; Lee H; Cho EY; Kim MS; Hwang MH; Kim SI; Ahn DH
Virus Res; 2015 Jun; 204():40-6. PubMed ID: 25892718
[TBL] [Abstract][Full Text] [Related]
9. Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production.
Liu J; Mani S; Schwartz R; Richman L; Tabor DE
Vaccine; 2010 Feb; 28(5):1285-93. PubMed ID: 19944150
[TBL] [Abstract][Full Text] [Related]
10. HA and M2 sequences alter the replication of 2013-16 H1 live attenuated influenza vaccine infection in human nasal epithelial cell cultures.
Canaday LM; Resnick JD; Liu H; Powell H; McCoy AM; Nguyen D; Pekosz A
Vaccine; 2022 Jul; 40(32):4544-4553. PubMed ID: 35718589
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and efficacy of the monovalent, trivalent and quadrivalent intranasal live attenuated influenza vaccines containing different pdmH1N1 strains.
Yeolekar LR; Ganguly M; Tyagi P; Ingle NB; Stittelaar KJ; Waal L; Scorza FB; Mahmood K; Dhere RM
Vaccine; 2018 Nov; 36(46):6944-6952. PubMed ID: 30322745
[TBL] [Abstract][Full Text] [Related]
12. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries.
Rudenko L; van den Bosch H; Kiseleva I; Mironov A; Naikhin A; Larionova N; Bushmenkov D
Vaccine; 2011 Jul; 29 Suppl 1():A40-4. PubMed ID: 21684428
[TBL] [Abstract][Full Text] [Related]
13. Proteomics as a tool for live attenuated influenza vaccine characterisation.
Hawksworth A; Jayachander M; Hester S; Mohammed S; Hutchinson E
Vaccine; 2020 Jan; 38(4):868-877. PubMed ID: 31708181
[TBL] [Abstract][Full Text] [Related]
14. Use of MDCK cells for production of live attenuated influenza vaccine.
Liu J; Shi X; Schwartz R; Kemble G
Vaccine; 2009 Oct; 27(46):6460-3. PubMed ID: 19559113
[TBL] [Abstract][Full Text] [Related]
15. Alternative Strategy for a Quadrivalent Live Attenuated Influenza Virus Vaccine.
Wan Z; Cardenas Garcia S; Liu J; Santos J; Carnaccini S; Geiger G; Ferreri L; Rajao D; Perez DR
J Virol; 2018 Nov; 92(21):. PubMed ID: 30135124
[TBL] [Abstract][Full Text] [Related]
16. Safety, Immunogenicity, and Protective Efficacy of a Chimeric A/B Live Attenuated Influenza Vaccine in a Mouse Model.
Stepanova E; Krutikova E; Wong PF; Matyushenko V; Bazhenova E; Isakova-Sivak I; Rudenko L
Microorganisms; 2021 Jan; 9(2):. PubMed ID: 33513862
[TBL] [Abstract][Full Text] [Related]
17. Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses.
Kiseleva I; Dubrovina I; Fedorova E; Larionova N; Isakova-Sivak I; Bazhenova E; Pisareva M; Kuznetsova V; Flores J; Rudenko L
Vaccine; 2015 Dec; 33(49):7008-14. PubMed ID: 26432909
[TBL] [Abstract][Full Text] [Related]
18. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
[TBL] [Abstract][Full Text] [Related]
19. A bivalent live-attenuated influenza vaccine for the control and prevention of H3N8 and H3N2 canine influenza viruses.
Rodriguez L; Nogales A; Murcia PR; Parrish CR; MartÃnez-Sobrido L
Vaccine; 2017 Aug; 35(34):4374-4381. PubMed ID: 28709557
[TBL] [Abstract][Full Text] [Related]
20. Replication of live attenuated influenza vaccine viruses in human nasal epithelial cells is associated with H1N1 vaccine effectiveness.
Hawksworth A; Lockhart R; Crowe J; Maeso R; Ritter L; Dibben O; Bright H
Vaccine; 2020 May; 38(26):4209-4218. PubMed ID: 32376111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
